Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T12:50:39.340Z.
Calculation as of: 2026-10-06T12:50:39.340Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2e8745362276acfcd64f5b9abcba69827836693d7b304a16c872192b0535814a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Bicara Therapeutics Inc. Common Stock
Market Cap
$1.14B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.14B
Price/FCF Ratio
215.15
TTM Avg
118.53
3Y Avg
218.34
5Y Avg
165.60
Market Cap
$1.12B
Price/FCF Ratio
N/A
TTM Avg
56.73
3Y Avg
40.99
5Y Avg
56.97
Market Cap
$1.12B
Price/FCF Ratio
7.32
TTM Avg
8.70
3Y Avg
12.19
5Y Avg
18.11
Market Cap
$1.16B
Price/FCF Ratio
7.99
TTM Avg
9.04
3Y Avg
20.26
5Y Avg
32.54
Market Cap
$1.20B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.21B
Price/FCF Ratio
24.43
TTM Avg
2775.83
3Y Avg
1287.19
5Y Avg
1287.19
Market Cap
$1.22B
Price/FCF Ratio
24.20
TTM Avg
28.25
3Y Avg
29.31
5Y Avg
46.12
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bicara Therapeutics Inc. Common Stock (BCAX) | $1.14B | N/A | N/A | N/A | N/A |
| Harrow Health, Inc. (HROW)vs › | $1.14B | 215.15 | 118.53 | 218.34 | 165.60 |
| Castle Biosciences, Inc. (CSTL)vs › | $1.12B | N/A | 56.73 | 40.99 | 56.97 |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.12B | 7.32 | 8.70 | 12.19 | 18.11 |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.16B | 7.99 | 9.04 | 20.26 | 32.54 |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.20B | N/A | N/A | N/A | N/A |
| Cronos Group Inc. (CRON)vs › | $1.21B | 24.43 | 2775.83 | 1287.19 | 1287.19 |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | 4.68 | 5.48 | 6.82 | 13.79 |
| Innovage Holding Corp. (INNV)vs › | $1.22B | 24.20 | 28.25 | 29.31 | 46.12 |
| Immatics N.V. (IMTX)vs › | $1.04B | N/A | 6.28 | 5.25 | 24.15 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
